AIP
CRNX icon

Almanack Investment Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Almanack Investment Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,001
Closed -$19K – 382
2022
Q3 		$19K Buy
+1,001
New +$20.4K ﹤0.01% 384

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Almanack Investment Partners's CRNX Position: Q4 2022 in Review

Almanack Investment Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2022, closing a stake of 1,001 shares — an estimated $19K sold.

Almanack Investment Partners first reported a position in CRNX in Q3 2022 and held it in 1 quarter. The position peaked at $19K in Q3 2022. 122 funds tracked by Wall St. Rank hold CRNX as of Q4 2022.

  • Almanack Investment Partners reported no remaining Crinetics Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 1,001 Crinetics Pharmaceuticals shares in Q4 2022, an estimated $19K.
  • Almanack Investment Partners first reported a position in Crinetics Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Crinetics Pharmaceuticals position peaked at $19K in Q3 2022.
  • 122 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.